RxDoctor Payments Data

Jonathan Kaufman, MD

Ophthalmology · Zephyrhills, FLNPI 1578896155

Payments from drug & device makers

$749in general payments, 2019–2025

Across 35 payments — averaging $21.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$348
  • Alcon$205
  • Sun Pharmaceutical Industries Inc.$69
  • Rxsight Inc$27
  • Biotissue Holdings Inc.$24
  • Bausch & Lomb Americas Inc.$18
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$69192%
  • Education$588%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$749 in reported general payments places this provider in the 30th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$529,726
Medicare patients
1,280
Services billed
5,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine107$106,377
Prednisolone Acetate569$28,380
LumiganBimatoprost32$23,635
Cyclosporine29$23,331
RocklatanNetarsudil Mesylat/Latanoprost17$19,314
Latanoprost1,148$16,911
RhopressaNetarsudil Mesylate21$12,625
MoxifloxacinMoxifloxacin Hcl481$11,163
Travoprost26$7,525
Brinzolamide21$6,161
Flurbiprofen Sodium225$5,903
Timolol Maleate399$5,128
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$4,950
Dorzolamide Hcl164$4,728
Diclofenac Sodium349$3,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$348$130,011139 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$14$31,93938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Zephyrhills

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →